WeedLife News Network

Nature’s Medicines, which has two medical marijuana dispensaries in the Valley, has announced that they’ve launched a medical marijuana delivery service in the Phoenix metro area.

“Our medical marijuana patients will now be able to order their favorite cannabis products at our low dispensary prices without the markup charged by other delivery services and get them delivered right to their front door,” said CEO Jigar Patel.

European Industrial Hemp Association Managing Director Lorenza Romanese tells MCN about Novel Foods legislation and industrial hemp in the EU.

The European Industrial Hemp Association (EIHA), founded in 2005, is the only pan-European membership body serving the industrial hemp sector, boasting members from 25 EU Member States and 12 third countries.

A cadre of lawyers, accountants, insurers and real estate agents expect big returns from the start of adult-use marijuana sales in Maine on Oct. 9 as companies seek professional help to navigate the complicated new market.

While they had previously shied away from touting their “green business” clientele in Maine, those professionals now are openly advertising specialties in the highly regulated recreational marijuana business as it comes with increasing oversight at the state and federal levels.

MCN speaks with Australia’s Therapeutic Goods Administration about medical cannabis regulation and access.

The Australian Therapeutic Goods Administration (TGA), which operates under the aegis of the Department of Health, is responsible for regulating therapeutic goods – including pharmaceutical and complementary medicines, medical devices, tests, and vaccines – across Australia. It oversees the classification and manufacture of medicines and medicinal products; as well as conducting risk and safety assessments, standards enforcement, and post-market monitoring.

As the regulatory body in charge of determining the validity of applications to prescribe medical cannabis, the TGA has approved requests for cannabis prescriptions to treat conditions and symptoms including:

It should be noted, however, that applying to prescribe cannabis for one of the above conditions does not guarantee approval from the TGA.

MCN speaks with a spokesperson from the TGA about Australian cannabis regulation and access, the evolution of Australian cannabis policy, and the importance of continued education within the sector.

What is the current medical and legal status of cannabis in Australia?

Australia is a signatory to the United Nations Single Convention on Narcotic Drugs of 1961, as amended, which requires all signatories to implement controls on the cultivation of the cannabis plant. Commentary to the Single Convention provides an overview of the standard regime to which signatories have committed:

There's no question that this is going to be a big decade for the technology sector. We're liable to see a demand explosion for cloud computing, cybersecurity, and Internet of Things devices. But don't sleep on the marijuana industry.

Although Wall Street estimates vary wildly, as we'd expect from an industry with no modern-day precedent, global sales could hit anywhere from $50 billion to $200 billion a year by 2030. For some context here, worldwide legal weed sales didn't even hit $11 billion in 2018.

But every fast-growing industry encounters growing pains. In Canada, regulatory issues have constrained supply. Meanwhile, in the U.S., high tax rates on legal weed have made it difficult for licensed producers to compete with the black market.

In 2020, state courts still seem to be a good bet for cannabis businesses in cannabis-legal states. But federal courts are sliding backward.

A few weeks back, the Cannabis Law Institute invited me to discuss contract drafting for cannabis deals. A focal point for the panel was whether courts are willing to enforce cannabis contracts. The last time I had really looked at that issue was early 2019, when I wrote: Cannabis Dispute? Courts are Open. As the title indicates, my research (and our law firm’s experience) showed that both state and federal courts were generally open to resolving cannabis contract disputes at the time. And I assumed the trend had held. Unfortunately, it has not!

In the 2019 piece, I summarized:

[Contract enforceability] was always the biggest consideration in choosing a forum for cannabis disputes. A few months ago, we ran a survey of federal courts and cannabis litigation, observing that none of the districts at issue were invalidating state-sanctioned businesses’ cannabis contracts on the dreaded “illegal purpose” basis. This trend is holding strong in recent federal court disputes on issues from RICO to patent infringement, despite the prohibited status of “marijuana” under federal law. As to state courts, the decisions declining to hear cannabis beefs are pretty far in the rearview. (Ironically, it has been safer overall to enforce cannabis contracts in federal courts that state courts to date.) When drafting agreements for cannabis clients, we still advise as to the diminishing possibility of non-enforcement, but most cannabis companies seem comfortable choosing court over arbitration if other goals are satisfied.

In 2020, state courts still seem to be a good bet for cannabis businesses in cannabis-legal states. Although I have not run a formal survey, I also have not come across local courts tossing disputes solely because the contract related to cannabis activities (and our cannabis business litigators have worked on many of these cases). But federal courts are sliding backward. A trio of cases in Washington, Oregon and Nevada show why.

As federal marijuana legalization in the United States remains off the table, a non-profit coalition of reform advocates and businesses in the pot industry is pursuing a plan to legalize interstate cannabis commerce next year. 

As reported by Marijuana Moment this week, the Alliance for Sensible Markets has released a plan under which the group will urge governors across the country to enter interstate compacts in order to facilitate the movement of cannabis between states where pot has been legalized.

An interstate compact represents an agreement allowed under the U.S. Constitution between two or more states, which depending on the subject matter needs congressional approval. 

Throughout all the major cannabis news that has been making headlines in Europe, the U.S., and across the globe over the past ten or so years, France has been almost nowhere in the mix.

A parliamentary committee wants to change that as soon as possible and the members are urging the government to initiate a medical cannabis experiment and figure out the best way to address medical cannabis concerns. 

An Urgent Call To Action

The committee made this demand in a document, asking for a budget that would support some kind of experiment surrounding medical cannabis and its potential for legalization. 

“It’s very important that funding for the medical cannabis experiment is now integrated into this process,” said  Benjamin-Alexandre Jeanroy, CEO of Augur Associates in Paris, back in 2019 regarding the importance of moving forward and making something happen. While France has technically approved such an experiment a year ago through legal channels, there needs to be actual implementation to get something off the ground and into the trial stage so that progress can be monitored.  

Robin Reda of the French National Assembly and president of the committee claims that she believes France “has fallen alarmingly behind its European neighbors” in terms of cannabis reform overall. “The bulk of the technical work was done before the health crisis,” Reda added, explaining that she doesn’t believe this delay is due to COVID alone, as there has been plenty of time. She instead blames “bureaucratic blockage” and wonders why the government is not moving forward. 

Could marijuana legalization be on its way to South Dakota? As if 2020 couldn’t get any stranger, a new poll suggests that voters in the Mount Rushmore State could be ready to take the leap.

The survey, conducted by South Dakota-based marketing firm Lawrence and Schiller and conservative pollster Public Opinion Strategies on behalf of a group opposed to legalization, found that about 60 percent of voters intend to vote for Constitutional Amendment A, a proposal to allow adults aged 21 and over to use marijuana. 

There is, however, a significant caveat to the data. Constitutional Amendment A is not the only pot-related proposal on South Dakota’s ballot this November. There is also Initiated Measure 26, which would make medical cannabis legal in the state.

The poll was organized by the South Dakota Chamber of Commerce and Industry on behalf of the group “No Way On A.”

“Going back to the numbers, we know that a significant portion of that majority for (legalized recreational marijuana use) thinks it’s related to medical,” Chamber President David Owen told the Argus Leader newspaper. 

Hill Dickinson Senior Associate Rohit Fogla explores the UK’s regulatory landscape concerning cannabis finance.

As policy on cannabis in the UK and Europe continues to evolve, Rohit Fogla, Senior Associate at Hill Dickinson LLP, outlines the current regulatory regime for medical cannabis, capital raising and investment options for enterprises and investors operating in this sector.

Medical cannabis in the UK

In November 2018, the UK government changed the law to make it possible for ‘cannabis-based products for medicinal use in humans’ (CBPMs) to be ordered and prescribed by specialist practitioners without a controlled drugs licence. At the time, it was thought this might be the gateway to further liberalisation of the restrictions on cannabis in the UK, which would foster the development of a UK medical cannabis industry.

However, due to restrictions put in place around the reforms that were introduced, only a very small number of patients with a limited range of conditions have been able to access treatment within the NHS, meaning that medical cannabis remains inaccessible for many of the patients in need.

One of the main barriers to access has been doctors’ inability or unwillingness to prescribe medicinal cannabis. This is partly due to the lack of education around cannabis available to doctors, but also due to the responsibility placed on doctors who elect to pursue this form of treatment. This has meant that those people that cannot access medical cannabis on the NHS or privately, which some estimates suggest run to the millions, are forced to purchase cannabis on the black market.

It will be quite some time before we understand the full impact of the COVID-19 pandemic. But history tells us one important thing: during times of crisis, how an industry is regulated often affects its ability to adapt and survive or even gain advantage.

Take payments and banking. While most brick-and-mortar retailers have been instituting contactless transactions to meet changing customer expectations and prevent the spread of the virus, cannabis dispensaries in the U.S. are still largely operating with cash only. They cannot accept major credit cards because marijuana is illegal under federal law. And now they’re facing a nationwide coin shortage.

With the coronavirus crippling economic activity in the U.S., the circulation of coins has dropped off significantly. Hardest hit has been restaurants, laundromats, convenience stores, arcades, and supermarket chains—businesses that rely on the flow of paper currency and need to make change. Yet unlike dispensaries, these businesses can more easily accept alternative forms of payments. 

“We still can’t operate like other businesses, unfortunately,” says Jerry Millen, owner of the Greenhouse of Walled Lake, a fully licensed medical and recreational cannabis dispensary in Michigan.

“First we ran out of pennies,” Millen says of the coin shortage. “We didn’t want to gouge the patient or the customer, so we rounded [transactions] down, which didn’t cost us a whole lot. But then we started running out of quarters, and suddenly we started to feel an impact.”

Mixing CBD and coffee is a fast-growing trend among CBD oil users — and for a good reason.

It’s more than just a commercial trend; there are real benefits to mixing CBD with coffee. The calming effects of CBD help reduce the unwanted side-effects of caffeine, such as anxiety and jitteriness. At the same time, CBD is able to enhance the mental alertness provided by your cup of morning coffee.

Would you try this win-win combo yourself?

Then you’ve come to the right place. In this article, we explain everything you need to know about mixing CBD and caffeine. We’ll cover the potential benefits, go over proper dosing, and share a few tips and tricks for using this combination to the fullest.

A Primer on Coffee, the Most Popular Stimulant on Earth

Coffee is by far the most popular stimulant brewed in the world. According to various estimates, people consume over 2.2 billion cups of coffee every day.

Two County Cavan farmers believe that growing hemp could help bring life back to rural Ireland. 

Kim Kindersley and Michael Ó Lionsaigh have been producing CBD oil from their hemp crops as global demand for the oil increases due to its perceived medical qualities. 

Both farmers believe that the cannabis plant, which is one of the oldest cultivated crops in Ireland, could help reinvigorate rural Ireland and Irish farming. 

Hemp was once extensively grown in Ireland to produce ropes, riggings and sails for ships at a time when sailing was the chief mode of transport. 

Now, the plant is used to make CBD oil, which consists of less than 0.3% THC. THC is a psychoactive that produces the highs associated with cannabis use. 

A nearly three-year-old case, Washington v. Barr, which pits former NFL star Marvin Washington and plaintiffs against Attorney General William Barr, received a boost this week.

A slew of organizations, including the National Organization for the Reform of Marijuana Laws (NORML), Americans for Safe Access and U.S. law firm Ansell Grimm & Aaron have joined the fight, filing amicus briefs in the case, which challenge the constitutionality of weed’s Schedule 1 status.

If the Supreme Court of the United States chooses to hear the case, it could change U.S. drug policy.

“Patients today face an untenable choice,” cannabis attorney Joshua Bauchner said in a statement. “They can either risk federal prosecution for using medical cannabis in accordance with state and local laws at the advice of their doctors, or risk serious, even fatal, health consequences. This is an unacceptable trade-off that no one should be forced to make any longer,” Bauchner argued.

Ansell, Grimm & Aaron are representing five organizations with a vested interest in the case, including Athletes for CARE, a non-profit of former pro athletes turned cannabis advocates, After The Impact Fund, an organization that helps military vets and ex-athletes receive treatment for post-traumatic stress disorder, anxiety and depression, among other conditions, and NFL Sisters in Service, Inc., a non-profit comprised of the spouses, daughters and mothers of current and former NFL players who advocate on behalf of those players.

Zimbabwe has announced the rules for growing cannabis, as the country seeks to boost foreign currency revenue and benefit from the rapidly growing industry.

Anxious Masuka, the agriculture minister, under regulations published in a government gazette said three types of permits can be issued for growers, researchers and industrial hemp merchants.

Growers are only allowed to cultivate, market and sell industrial hemp and researchers may cultivate for research purposes. A merchant can contract individual farmers, procure and process industrial hemp into a specified product.

Prior to the new rule people found growing cannabis in Zimbabwe were liable to a jail term of up to 12-years.

From hash to heroin, Hong Kong has a reputation for being hard on drugs. But one business has managed to work its way around the region’s strict cannabis prohibition laws.

Found Café will offer a plethora of snacks and beverages such as biscuits, coffee, tea, juices, and even beer spiked with varying doses of CBD, Sky News reports.

Short for cannabidiol, CBD is a psychoactive but non-intoxicating compound derived from the cannabis plant that has exploded in popularity across the globe over the past few years.

The cannabinoid is used therapeutically for a variety of symptoms and ailments, ranging from inflammation to anxiety.

Patrons hoping for a high, however, will be disappointed to learn that none of the café’s offerings will include THC — tetrahydrocannabinol, the intoxicating compound in cannabis — which would cause the business to run afoul of local drug laws.

As reported by the Houston Chronicle, the city’s Forensic Science Center has devised a chemical testing procedure capable of differentiating between hemp and psychoactive cannabis. In June 2019, the law that defines hemp and ‘weed’ became effective: it distinguishes them from each basing on whether they are above 0,3% THC content. The maneuver, intended to serve as an added business safety for hemp farmers, created an issue at the prosecution level: THC content has to be proven, since this bill passed. And, a that time, Texas laboratories were not equipped to provide the analytical evidence that entities like state-licensers or prosecutors need to enact regulations.

Up to this day, state agencies were forced to rely on costly analyses services provided by private laboratories. This new testing method will be limited to the plants themselves, and will not be structured in a way to assess active principle content in any other form of cannabis products.  The procedure represents the fruit of more than a year of work, conducted by two lab employees, who adapted a DEA test methodology in order to serve them in the differentiation between hemp and marijuana.  Another peculiarity of this testing practice, besides working solely with plant material, is the fact that it accounts for a 0,3% THC ‘wiggle-room’, which should keep every party involved away from the risk of legal hassles coming from a false positive.

Texan hemp farmers, finally, can rely on the certainty that local law enforcement will be able to properly do their job and distinguish their operations from illicit or non-compliant ones, without the concerns caused by the lack of resources.

Can These Pot Stocks Continue to Compete Amidst the Cannabis Industry Competition?

Before giving CBD oil to your ailing dog or cat, you should know something.

It’s not legal to give your pet CBD oil, a popular treatment for humans looking for help with arthritis and a host of other problems.

When the Cannabis Act was passed by the federal government and updated later to include edibles, its use for pets was not included.

“Veterinarians are not permitted to authorize medical cannabis nor are there are any products that contain cannabinoids that are approved for use in animals,” said Sarah Silcox, president of the Canadian Association of Veterinary Cannabinoid Medicine.

“So the most promising step is the government has last year proposed a new class that they have termed cannabis health products, but they would be approved by Health Canada for both human products as well as animal products,” added Silcox, who predicted that change is at least a year away.

The passage of this bipartisan bill would help raise the quality and safety of hemp products, and thus, protect consumers.

Last week, Oregon Representative Kurt Schrader (D) and Virginia Representative Morgan Griffith (R) introduced The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 (“H.R. 8179”). If enacted in its current form, H.R. 8179 would legalize the manufacture, sale and marketing of hemp, hemp-derived cannabidiol and other hemp extracts (collectively referred to as “Hemp Products”) as dietary supplements under the Federal Food, Drug and Cosmetic Act (“FDCA”).

This means that these products would be exempt from the FDCA’s “Drug Exclusion Rule,” which, as we previously discussed, currently prevents the sale and marketing of any substance that has been approved or investigated by the FDA as a new drug as a conventional food or dietary supplement – In July 2018, the FDA approved CBD as a drug ingredient in Epidiolex.

To be compliant with the FDCA, these Hemp Products would need to meet the existing regulatory framework imposed on dietary supplements. This comprehensive regulatory framework mandates, in part, that these products be safe as well as properly labeled and marketed.

Because Hemp Products were not sold and marketed in the U.S. as dietary supplements or conventional foods before October 15, 1994, they would be deemed “new dietary ingredients” or “NDIs”.